Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863906 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL22283234 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL20733347 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL12243459 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL20864026 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL16401886 | 0.89 | NPC1 (0.44) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL25993243 | 0.86 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL15382657 | 0.85 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL30634406 | 0.85 | LSS (0.43) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL24252193 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ASPHK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390898-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-12-17 | — | — | US | claimed |
| US-10765625-B2 | Knottin-drug conjugates and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-08 | — | — | US | claimed |
| US-20170304342-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-10-26 | — | — | US | claimed |
| WO-2017160879-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-21 | — | — | WO | claimed |
| EP-4392456-A2 | ANTIBODIES HAVING HUMANIZED FRAMEWORK REGIONS | R.P. Scherer Technologies, LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12023321-B2 | Lasofoxifene treatment of aromatase-resistant ER+cancer | SERMONIX PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240182584-A1 | Bispecific Molecules and Related Compositions and Methods | HOWARD HUGHES MEDICAL INSTITUTE | 2024-06-06 | — | — | US | disclosed |
| US-11970546-B2 | Antibody specific for Mucin-1 and methods of use thereof | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024077170-A1 | ANTI-UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR ANTIBODIES AND METHODS OF USE | SHANGPHARMA INNOVATION, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4314050-A1 | BISPECIFIC MOLECULES AND RELATED COMPOSITIONS AND METHODS | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023009835-A9 | ANTIBODY CONJUGATES SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230416377-A1 | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-12-28 | — | — | US | disclosed |
| US-20200390898-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
| WO-2020237078-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-11-26 | — | — | WO | disclosed |
| US-10765625-B2 | Knottin-drug conjugates and methods of using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-08 | — | — | US | disclosed |
| WO-2020132100-A1 | BIFUNCTIONAL MOLECULES FOR LYSOSOMAL TARGETING AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200129631-A1 | PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-30 | — | — | US | disclosed |
| WO-2018170019-A1 | PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20170304342-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-10-26 | — | — | US | disclosed |
| WO-2017160879-A1 | KNOTTIN-DRUG CONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416377-A1 | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods | LAMP2, LAMP1, GAA | SMN1; SMN2 4054/4885NPC1 150/4885RAB9A 296/4885 |
| US-12023321-B2 | Lasofoxifene treatment of aromatase-resistant ER+cancer | ESR1, CYP19A1, BRCA1 | SMN1; SMN2 3231/4885NPC1 2183/4885RAB9A 1753/4885 |
| US-20200129631-A1 | PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME | POLQ, SYNCRIP, PCNA | SMN1; SMN2 1118/4885NPC1 1317/4885RAB9A 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.